Literature DB >> 27995573

Forskolin Induces Hyperphosphorylation of Tau Accompanied by Cell Cycle Reactivation in Primary Hippocampal Neurons.

Hai-Hong Wang1, Yan Li1, Ang Li1, Fang Yan1, Zhen-Lin Li1, Zhong-Ying Liu1, Lei Zhang1, Jian Zhang2, Wei-Ren Dong3, Lin Zhang4.   

Abstract

Abnormally hyperphosphorylated tau is the major protein constituent of neurofibrillary tangles (NFTs) in the brain of Alzheimer disease (AD) patients. Cell cycle reactivation is considered an important neuropathological feature of AD, and re-expression and activation of cell cycle regulators are known to occur in neurons containing NFTs. The aim of the present study was to investigate cell cycle reactivation during tau hyperphosphorylation in primary hippocampal neurons. We used forskolin, a specific activator of PKA, to induce tau hyperphosphorylation in cultured primary hippocampal neurons, and then measured levels of cyclin D1 and cyclin B1. We found that forskolin induced hyperphosphorylation of tau at Ser214, Ser396, and Ser202/Thr205 sites, attaining peak levels at 6, 12, and 12 h, respectively, while returning to normal levels at 24 h. Forskolin also induced a sustained cAMP elevation and PKA activation, which peaked at 6 h, in association with activation and overexpression of protein phosphatase-2A (PP-2A) at 24 h. The tau hyperphosphorylation was accompanied by increases in cyclin D1 and cyclin B1 levels; immunostaining showed overlapping distribution of hyperphosphorylated tau and cyclin D1 and cyclin B1 in primary hippocampal neurons. Forskolin induced hyperphosphorylation of tau and increased cyclin D1 and cyclin B1 protein levels in HEK293/tau441 cells, but not in the HEK293/vector cells, whereas the PKA inhibitor H89 inhibited the effects of forskolin on tau hyperphosphorylation and cyclin D1 and cyclin B1 protein levels. These findings suggest that forskolin induces tau hyperphosphorylation, which is itself necessary for the subsequent increases of cyclin D1 and cyclin B1 levels.

Entities:  

Keywords:  Alzheimer disease; Cell cycle reactivation; Phosphorylation; Tau

Mesh:

Substances:

Year:  2016        PMID: 27995573     DOI: 10.1007/s12035-016-0348-7

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  38 in total

Review 1.  Tau protein phosphatases in Alzheimer's disease: the leading role of PP2A.

Authors:  Ludovic Martin; Xenia Latypova; Cornelia M Wilson; Amandine Magnaudeix; Marie-Laure Perrin; Faraj Terro
Journal:  Ageing Res Rev       Date:  2012-07-06       Impact factor: 10.895

Review 2.  Tau protein kinases: involvement in Alzheimer's disease.

Authors:  Ludovic Martin; Xenia Latypova; Cornelia M Wilson; Amandine Magnaudeix; Marie-Laure Perrin; Catherine Yardin; Faraj Terro
Journal:  Ageing Res Rev       Date:  2012-06-26       Impact factor: 10.895

3.  Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.

Authors:  I Grundke-Iqbal; K Iqbal; Y C Tung; M Quinlan; H M Wisniewski; L I Binder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

4.  Activation of protein phosphatase 2A by cAMP-dependent protein kinase-catalyzed phosphorylation of the 74-kDa B'' (delta) regulatory subunit in vitro and identification of the phosphorylation sites.

Authors:  H Usui; R Inoue; O Tanabe; Y Nishito; M Shimizu; H Hayashi; H Kagamiyama; M Takeda
Journal:  FEBS Lett       Date:  1998-07-03       Impact factor: 4.124

5.  Swedish amyloid precursor protein mutation increases cell cycle-related proteins in vitro and in vivo.

Authors:  Kwang-Woo Ahn; Yuyoung Joo; Yoori Choi; Minji Kim; Sang Hyoung Lee; Seok-Ho Cha; Yoo-Hun Suh; Hye-Sun Kim
Journal:  J Neurosci Res       Date:  2008-08-15       Impact factor: 4.164

6.  A transitory activation of protein kinase-A induces a sustained tau hyperphosphorylation at multiple sites in N2a cells-imply a new mechanism in Alzheimer pathology.

Authors:  Y Zhang; H-L Li; D-L Wang; S-J Liu; J-Z Wang
Journal:  J Neural Transm (Vienna)       Date:  2006-02-09       Impact factor: 3.575

7.  Nmnat2 attenuates Tau phosphorylation through activation of PP2A.

Authors:  Xiang-Shu Cheng; Kun-Peng Zhao; Xia Jiang; Lai-Ling Du; Xiao-Hong Li; Zhi-Wei Ma; Jun Yao; Yu Luo; Dong-Xiao Duan; Jian-Zhi Wang; Xin-Wen Zhou
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

8.  A novel cAMP-stimulated pathway in protein phosphatase 2A activation.

Authors:  Marina S Feschenko; Elizabeth Stevenson; Angus C Nairn; Kathleen J Sweadner
Journal:  J Pharmacol Exp Ther       Date:  2002-07       Impact factor: 4.030

9.  A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads.

Authors:  E Braak; H Braak; E M Mandelkow
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

Review 10.  Neuronal cell cycle: the neuron itself and its circumstances.

Authors:  José M Frade; María C Ovejero-Benito
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

View more
  7 in total

Review 1.  Tau Toxicity in Neurodegeneration.

Authors:  Shu-Yu Liang; Zuo-Teng Wang; Lan Tan; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2022-03-31       Impact factor: 5.682

2.  PINK1 overexpression prevents forskolin-induced tau hyperphosphorylation and oxidative stress in a rat model of Alzheimer's disease.

Authors:  Xiao-Juan Wang; Lin Qi; Ya-Fang Cheng; Xue-Fei Ji; Tian-Yan Chi; Peng Liu; Li-Bo Zou
Journal:  Acta Pharmacol Sin       Date:  2021-12-10       Impact factor: 7.169

3.  Cdc42 Facilitates Axonogenesis by Enhancing Microtubule Stabilization in Primary Hippocampal Neurons.

Authors:  Ang Li; Hui-Ming Zhu; Yu Chen; Fang Yan; Zhong-Ying Liu; Zhen-Lin Li; Wei-Ren Dong; Lin Zhang; Hai-Hong Wang
Journal:  Cell Mol Neurobiol       Date:  2021-02-11       Impact factor: 5.046

4.  Exome sequencing revealed PDE11A as a novel candidate gene for early-onset Alzheimer's disease.

Authors:  Wei Qin; Aihong Zhou; Xiumei Zuo; Longfei Jia; Fangyu Li; Qi Wang; Ying Li; Yiping Wei; Hongmei Jin; Carlos Cruchaga; Bruno A Benitez; Jianping Jia
Journal:  Hum Mol Genet       Date:  2021-05-28       Impact factor: 5.121

5.  Tianma Formula Alleviates Dementia via ACER2-Mediated Sphingolipid Signaling Pathway Involving Aβ.

Authors:  Haochang Lin; Sha Wu; Zhiying Weng; Hongyan Wang; Rui Shi; Menghua Tian; Youlan Wang; Haiyan He; Yuchuan Wang; Xuan Liu; Zhimin Jian; Fuqin Wei; Peng Wang; Liuyi Zhang; Yi Liu; Qiuzhe Guo; Chen Chen; Weimin Yang
Journal:  Evid Based Complement Alternat Med       Date:  2021-08-04       Impact factor: 2.629

6.  Similarities and Differences in the Pattern of Tau Hyperphosphorylation in Physiological and Pathological Conditions: Impacts on the Elaboration of Therapies to Prevent Tau Pathology.

Authors:  Antoine Duquette; Camille Pernègre; Ariane Veilleux Carpentier; Nicole Leclerc
Journal:  Front Neurol       Date:  2021-01-07       Impact factor: 4.003

7.  Tau inhibits PKA by nuclear proteasome-dependent PKAR2α elevation with suppressed CREB/GluA1 phosphorylation.

Authors:  Jinwang Ye; Yaling Yin; Huanhuan Liu; Lin Fang; Xiaoqing Tao; Linyu Wei; Yue Zuo; Ying Yin; Dan Ke; Jian-Zhi Wang
Journal:  Aging Cell       Date:  2019-10-31       Impact factor: 9.304

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.